- Home
- CRBP vs GCTS Comparison
CRBP vs GCTS Comparison
Compare CRBP & GCTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- GCTS
- Stock Information
- Founded
- CRBP 2009
- GCTS 1998
- Country
- CRBP United States
- GCTS United States
- Employees
- CRBP N/A
- GCTS N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- GCTS Blank Checks
- Sector
- CRBP Health Care
- GCTS Finance
- Exchange
- CRBP Nasdaq
- GCTS Nasdaq
- Market Cap
- CRBP 73.4M
- GCTS 69.0M
- IPO Year
- CRBP N/A
- GCTS N/A
- Fundamental
- Price
- CRBP $7.34
- GCTS $1.04
- Analyst Decision
- CRBP Strong Buy
- GCTS Strong Buy
- Analyst Count
- CRBP 10
- GCTS 1
- Target Price
- CRBP $53.56
- GCTS $5.00
- AVG Volume (30 Days)
- CRBP 114.6K
- GCTS 720.4K
- Earning Date
- CRBP 05-06-2025
- GCTS 05-14-2025
- Dividend Yield
- CRBP N/A
- GCTS N/A
- EPS Growth
- CRBP N/A
- GCTS N/A
- EPS
- CRBP N/A
- GCTS N/A
- Revenue
- CRBP N/A
- GCTS $6,359,000.00
- Revenue This Year
- CRBP N/A
- GCTS $315.43
- Revenue Next Year
- CRBP $150.00
- GCTS $170.52
- P/E Ratio
- CRBP N/A
- GCTS N/A
- Revenue Growth
- CRBP N/A
- GCTS N/A
- 52 Week Low
- CRBP $4.64
- GCTS $0.96
- 52 Week High
- CRBP $61.90
- GCTS $5.65
- Technical
- Relative Strength Index (RSI)
- CRBP 52.51
- GCTS 37.11
- Support Level
- CRBP $7.05
- GCTS $1.01
- Resistance Level
- CRBP $7.62
- GCTS $1.10
- Average True Range (ATR)
- CRBP 0.49
- GCTS 0.20
- MACD
- CRBP -0.02
- GCTS -0.03
- Stochastic Oscillator
- CRBP 42.65
- GCTS 5.30
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About GCTS GCT Semiconductor Holding Inc. Common Stock
GCT Semiconductor Holding Inc is a designer and supplier of 5G and 4G LTE semiconductor solutions. It enabled fast and reliable 4G LTE connectivity to numerous commercial devices such as CPEs, mobile hotspots, routers, M2M applications, and smartphones, etc. The system-on-chip solutions integrate radio frequency, baseband modem, and digital signal processing functions, therefore offering complete 4G and 5G platform solutions with small form factors, low power consumption, high performance, high reliability, and cost-effectiveness.